Haemonetics Profit Margin

The latest profit margin for HAE is 7.12% as of June 2026. That compares with 12.13% in the prior-year period — down 41.3% year over year. That is below the Healthcare sector average of 21.34%. Investors often review this figure alongside Haemonetics's historical trend and sector peers before judging valuation or financial health.

Over the past year, HAE's profit margin moved from 12.13% to 7.12% — a 41.3% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Haemonetics's valuation or profitability profile.

Against Healthcare companies, HAE currently prints 7.12% for profit margin, while the sector average sits near 21.34%. That is roughly 66.6% below the sector mean. Large gaps often invite a closer look at Haemonetics's growth, margins, and balance sheet.

Profit Margin shows how effectively Haemonetics converts resources into returns. At 7.12%, HAE may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 12.13% in the prior-year period — down 41.3% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting HAE's profit margin (7.12%), review year-over-year change from 12.13%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.